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Abstract
Background: Although the ADA/EASD/IDF International Expert Committee recommends using hemoglobin A1c
(HbA1c) to define diabetes, the relation between HbA1c and cardiovascular disease (CVD) has not been thoroughly
investigated. We analyzed this relation using clinical data on Japanese individuals with hypercholesterolemia.
Methods: In the large-scale MEGA Study 7832 patients aged 40 to 70 years old with mild-to-moderate
hypercholesterolemia without CVD were randomized to diet alone or diet plus pravastatin and followed for >5
years. In the present subanalysis of that study a total of 4002 patients with baseline and follow-up HbA1c data
were stratified according to having an average HbA1c during the first year of follow-up <6.0%, 6.0%-<6.5%, or
≥6.5% and their subsequent 5-year incidence rates of CVD compared according to sex, low-density lipoprotein
cholesterol (LDL-C), and treatment arm.
Results: Overall, risk of CVD was significantly 2.4 times higher in individuals with HbA1c ≥6.5% versus <6.0%. A
similar relation was noted in men and women (hazard ratio [HR], 2.1; p <0.01 and HR, 3.0; p <0.01, respectively)
and was regardless of treatment arm (diet alone group: HR, 2.2; p <0.001; diet plus pravastatin group: HR, 1.8; p =
0.02). Spline curves showed a continuous risk increase according to HbA1c level in all subpopulations studied.
Conclusions: In hypercholesterolemic individuals the risk of CVD increases linearly with HbA1c level. This
significant contribution by elevated HbA1c to increased CVD is independent of pravastatin therapy, and thus
requires appropriate HbA1c management in addition to lipids reduction.
Keywords: Hemoglobin A1c (HbA1c), cardiovascular disease (CVD), hypercholesterolemia, HMG CoA reductase inhi-
bitor, pravastatin, MEGA Study
Background
Clinical markers such as fasting plasma glucose (FPG),
oral glucose tolerance test, and postprandial glucose are
commonly used to define diabetes or impaired glucose
tolerance [1-3]. However, in 2009 an International
Expert Committee assembled by the American Diabetes
Association (ADA), European Association for the Study
of Diabetes (EASD), and International Diabetes Federa-
tion (IDF) announced that HbA1c assay is a more reli-
able marker to diagnose diabetes, using a cutpoint of
≥6.5% [4]. Observational studies indicate that measuring
HbA1c, compared with a single measure of glucose con-
centration, better captures the impact of long-term gly-
cemic exposure and severity of diabetic complications.
Epidemiologic data have also demonstrated relations
between HbA1c and microvascular and macrovascular
disease [5-7]. On the other hand, data are scarce for
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hypercholesterolemia.
This subanalysis evaluated the relation between
HbA1c and CVD using data from the long-term, large-
scale Management of Elevated Cholesterol in the Pri-
mary Prevention Group of Adult (MEGA) Study con-
ducted in Japan in the late 1990s to mid-2000s [8,9].
Methods
The design, baseline characteristics, and major outcomes
of the prospective, randomized, open-label, blinded end-
points MEGA Study have been described previously
[8,9]. Briefly, 7832 patients (2476 men and 5356 postme-
nopausal women) aged 40-70 years with mild-to-moder-
ate hypercholesterolemia (total cholesterol [TC] level,
5.7-6.0 mmol/L) without CVD were randomly allocated
to either the diet group or diet plus pravastatin (10-20
mg/day, the approved dose in Japan) group for a mean
follow-up period of 5.3 years. Patients in both arms
were counseled to follow the National Cholesterol Edu-
cation Program (NCEP) Step I diet [10] throughout the
study period. Pravastatin was initiated at 10 mg/day;
however, if the TC level did not decrease to ≤5.7 mmol/
L the dosage could be uptitrated to 20 mg/day, in com-
pliance with Japanese dosing instructions. Patients
whose TC remained >5.7 mmol/L, even after enhance-
ment of assigned treatment, could be switched to other
aggressive treatments including other statins. Concomi-
tant treatment for complications was not restricted in
both groups. The primary composite endpoint was first
occurrence of coronary heart disease (CHD) comprising
fatal and nonfatal myocardial infarction, angina pectoris,
cardiac/sudden death, and coronary revascularization
procedure. Secondary endpoints included all strokes,
CHD plus ischemic stroke, all CVD events, and total
mortality.
Patients were evaluated by their attending physician at
1, 3, and 6 months and every 6 months thereafter.
Health checkups at each clinic visit included biochem-
ical tests, including HbA1c levels, and assessment of
patient adherence to treatment. For each event, detailed
information was obtained from physicians and evaluated
by the blinded Endpoints Committee according to estab-
lished criteria. TC, high-density lipoprotein cholesterol
(HDL-C), triacylglycerides (TG), and lipoprotein(a) (Lp
[a]) levels were centrally measured at the same labora-
tory using methods standardized by the Centers for Dis-
ease Control and Prevention (Atlanta, GA). Low-density
lipoprotein cholesterol (LDL-C) level was estimated by
Friedewald’s formula. Fasting glucose, HbA1c, and other
laboratory values were measured at each participating
institution. Because the Japan Diabetes Society (JDS)
method was used to measure HbA1c, which has values
that are 0.3%-0.4% percent lower than National
Glycohemoglobin Standardization Program (NGSP)
values [11], for this report we converted all HbA1c
values to NGSP values by the following formula: HbA1c
(%) = 0.0981 × International Federation of Clinical
Chemistry (IFCC) value (mmol/L) [10.39 × JDS value
(%) - 16.8] + 1.95 [12].
We analyzed data on patients whose HbA1c value was
determined during the first 12 months of the study (5
values per patient; baseline, and at 1, 3, 6 and 12
months). Using these data, we assessed relations
between average HbA1c value for the first 12 months
and occurrence of CVD events including myocardial
infarction, angina, cardiac and sudden death, a coronary
revascularization procedure, stroke, transient ischemic
attack, and arteriosclerosis obliterans occurring during
the 5 years of follow-up. Event rates were compared for
three categories of HbA1c levels such as <6.0%, 6.0%-
<6.5%, and ≥6.5% using the new criteria from the Inter-
national Expert Committee [4]. Hazard ratios (HRs) and
95% confidence intervals (95%CIs) were estimated by
multivariate Cox proportional hazards model. Relations
between HbA1c and risk of CVD events were evaluated
by multivariable Cox proportional hazards model with
restricted quadratic spline [13]. The three knots for
quartiles were adopted as optimal analysis model for
this study, based on the results of comparison of a
model using two and four knots for HbA1c tertiles and
quintiles and that using three knots for 5.0%, 6.0%, and
7.0% of HbA1c. The multivariate models were simulta-
n e o u s l ya d j u s t e db ys e x ,a g e , treatment arm, baseline
LDL-C, baseline HDL-C, hypertension, chronic kidney
disease (estimated glomerular filtration rate <60), and
smoking status.
Results
Baseline clinical and demographics characteristics of the
4002 patients included in this analysis are summarized
in Table 1. Two thirds of the patients (66%) were
women; men were about 4 years younger than women
and had a slightly higher BMI. Confirmed diabetes, and
consequently average FPG and HbA1c, were higher in
men, whereas confirmed hypertension was higher in
women. LDL-C and HDL-C were somewhat lower, and
TG higher, in men than women.
The incidence of cardiovascular events in men and
women was compared among the three categories of
H b A 1 cl e v e l sa ss h o w ni nT a b l e2 .C o m p a r i n gt h e
≥6.5% versus <6.0% HbA1c group overall, CHD was sig-
nificantly higher (HR, 3.1; p <0.01), and also in men
(HR, 2.3; p <0.01) and women (HR, 4.9; p <0.01). More-
over, CVD was significantly increased (HR, 2.4; p <0.01),
and in men (HR, 2.1; p <0.01) and women (HR, 2.9; p
<0.01). As the HbA1c level increased, the incidence of
CHD and CVD increased. Whereas, stroke incidence
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total population and in men and in women, although it
did not reach statistical significance. In men, but not
women, there was a significant trend for increased mor-
tality as HbA1c levels increased.
Comparing patients whose HbA1c was ≥6.5% versus
<6.0% by treatment arm revealed that CVD was signifi-
cantly increased in the diet alone group (HR, 2.2, p
<0.001) and similarly in diet plus pravastatin group (HR,
1.8; p = 0.02; Figure 1) in patients with HbA1c ≥6.5%.
The spline curves for CVD exhibited a linear increase in
risk as HbA1c increased until approximately HbA1c
<6.0%; thereafter the risk increased more gently (Figure
2). Although CVD risk was proportionally lower in
women than men, no large difference in the shape of
the spline curves was found between the two sexes.
Discussion
We found a significant relation between having an
HbA1c level ≥6.5% and risk of CVD in Japanese patients
with hypercholesterolemia. This analysis compared three
categories of HbA1c levels as measured according to
new International Expert Committee criteria. Significant
relations between increased HbA1c level and CHD and
CVD were observed in men and women. A continuous
increase in CVD risk as HbA1c level rose was confirmed
by the spline method, which indicated that there is no
threshold between CVD risk and HbA1c level. Recent
reports have demonstrated that including HbA1c level
in the assessment model could help to identify subjects
at high risk, and that the predictability was improved by
also including lipid levels [14]. Therefore, evaluating the
relationship between HbA1c and CVD in patients with
hypercholesterolemia is important to identify patients in
a high-risk population.
The incidence of microvascular disease is known to
increase with higher HbA1c levels. For instance, diabetic
retinopathy occurs at a high rate in persons with HbA1c
>6.0%-7.0% [15]. The Kumamoto Study in Japan demon-
strated that the risk of retinopathy and nephropathy
starts to increase as HbA1c rises above 6.6%-6.7%
(NGSP) [16]. Macrovascular disease also is affected by a
high HbA1c. In the Framingham Heart Study, a 1%
increase in HbA1c was associated with a 1.39-fold
increased risk of CVD [17]. A graded association
between HbA1c and carotid intima-media thickness was
found in the Atherosclerosis Risk in Communities
(ARIC) study [18]. The Suita Study [11] recently
reported a significantly increased risk of CVD associated
with high HbA1c. Although it appears clear from these
epidemiologic data and interventional studies that
increased HbA1c levels are associated with raised CVD
risk, we believe that the present findings are the first
such demonstration in the setting of hypercholesterole-
mia, which itself confers high risk for CVD. Our data
indicate that the significant relation between CVD risk
and HbA1c ≥6.5% observed in hypercholesterolemia is
similar to that seen in the general population.
In our previous report, we stated that the incidence of
CVD in patients with or without abnormal fasting glu-
cose was 16.5 and 5.7 per 1000 patient-years, respec-
tively. In the present study, the incidences of CVD in
patients with HbA1c ≥ 6.1% and <6.1% were 16.9 and
6.1 per 1000 patient-years, respectively [19]. Although
the results are broadly consistent when using fasting
glucose and HbA1c as markers for glucose abnormalities
to determine the HRs, 5% of the patients with HbA1c
≥6.1% actually had normal fasting glucose levels (data
not shown). Since the HbA1c level is affected by post-
prandial glucose excursions more than the fasting glu-
cose level [20], evaluating HbA1c in addition to fasting
glucose is useful to identify people at high risk.
Statins can reduce CVD onset in the settings of pri-
mary and secondary prevention [21-25]. Benefits of sta-
tin therapy have been reported in patients with diabetes
[9,19,26] and confirmed in a large-scale meta-analysis
that implied that statins reduce CVD risk in diabetic
and nondiabetic populations [27]. In this study, although
statistical significance was not reached probably due to
the small number of events, we nonetheless observed a
proportional risk reduction in each HbA1c category in
the diet plus pravastatin group compared with diet
alone group (in patients with HbA1c <6.0%, 6.0%-<6.5%,
and ≥6.5%, HR = 0.64, 0.72, and 0.81, respectively).
Table 1 Baseline characteristics of patients
Variable Men Women Total
n 1374 2628 4002
Age, years 55.5 ± 8.1 59.8 ± 6.0 58.3 ± 7.1
BMI, kg/m
2 24.1 ± 2.8 23.8 ± 3.4 23.9 ± 3.2
Diabetes, n (%) 626 (45.6) 870 (33.1) 1496 (37.4)
Hypertension, n (%) 514 (37.4) 1108 (42.2) 1622 (40.5)
Current smoker, n (%) 518 (37.7) 145 (5.5) 663 (16.6)
TC, mmol/L 6.24 ± 0.31 6.29 ± 0.32 6.27 ± 0.32
LDL-C, mmol/L 4.01 ± 0.47 4.08 ± 0.43 4.06 ± 0.45
HDL-C, mmol/L 1.36 ± 0.36 1.54 ± 0.38 1.48 ± 0.38
Non-HDL, mmol/L 4.88 ± 0.46 4.76 ± 0.48 4.80 ± 0.48
TG (median [IQR]), mmol/L 1.71
(1.26-2.45)
1.33
(1.01-1.80)
1.44
(1.08-2.01)
FPG, mmol/L 6.80 ± 2.27 6.15 ± 1.80 6.37 ± 2.00
HbA1c, % 6.47 ± 1.38 6.22 ± 1.16 6.31 ± 1.24
Oral hypoglycemic agent, n (%) 291 (21.2) 423 (16.1) 714 (17.8)
Insulin, n (%) 55 (4.0) 98 (3.7) 153 (3.8)
Values are mean ± SD unless otherwise indicated.
Diabetes and hypertension defined by physician diagnosis. BMI, body mass
index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C,
high-density lipoprotein cholesterol; TG, triacylglycerides; FPG, fasting plasma
glucose; IQR, interquartile range.
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Page 3 of 6Table 2 Incidence of CVD events in relation to HbA1c level
% HbA1c Men Women All
Events/pts, n
(/1000 py)
HR
(95%CI)
p-
value
Trend-
p
Events/pts, n
(/1000 py)
HR
(95%CI)
p-
value
Trend-
p
Events/pts, n
(/1000 py)
HR
(95%
CI)
p-
value
Trend-p
CHD <0.01 <0.01 <0.01
<6.0 16/630 (5.6) 1.0 – 9/1481 (1.3) 1.0 – 25/2111 (2.6) 1.0 –
6.0-< 6.5 7/226 (7.1) 1.2
(0.5-2.9)
0.73 6/419 (3.2) 2.1
(0.7-6.0)
0.16 13/645 (4.5) 1.5
(0.8-2.9)
0.24
≥6.5 33/518 (14.7) 2.3
(1.3-4.2)
<0.01 24/728 (7.2) 4.9
(2.2-10.6)
<0.01 57/1246 (10.3) 3.1
(1.9-5.0)
<0.01
Stroke (all) 0.33 0.14 0.07
<6.0 11/630 (3.9) 1.0 – 13/1481 (1.9) 1.0 – 24/2111 (2.5) 1.0 –
6.0-< 6.5 5/226 (5.0) 1.1
(0.4-3.3)
0.82 4/419 (2.1) 1.0
(0.3-3.0)
0.94 9/645 (3.1) 1.1
(0.5-2.3)
0.85
≥6.5 15/518 (6.5) 1.5
(0.7-3.2)
0.33 14/728 (4.2) 1.8
(0.8-3.9)
0.13 29/1246 (5.1) 1.7
(1.0-2.9)
0.07
CVD <0.01 <0.01 <0.01
<6.0 27/630 (9.6) 1.0 – 26/1481 (3.9) 1.0 – 53/2111 (5.6) 1.0 –
6.0-< 6.5 12/226 (12.2) 1.2
(0.6-2.3)
0.69 10/419 (5.4) 1.2
(0.6-2.5)
0.64 22/645 (7.7) 1.2
(0.7-2.0)
0.48
≥6.5 50/518 (22.9) 2.1
(1.3-3.4)
<0.01 42/728 (12.8) 2.9
(1.8-4.7)
<0.01 92/1246 (16.9) 2.4
(1.7-3.4)
<0.01
Death (total) 0.01 0.53 0.04
<6.0 4/630 (1.4) 1.0 – 16/1481 (2.3) 1.0 – 20/2111 (2.1) 1.0 –
6.0-< 6.5 5/226 (4.9) 3.4
(0.9-12.9)
0.07 10/419 (5.2) 2.2
(1.0-4.9)
0.05 15/645 (5.1) 2.3
(1.2-4.4)
0.02
≥6.5 16/518 (6.7) 4.1
(1.3-12.5)
0.01 10/728 (2.9) 1.2
(0.5-2.6)
0.68 26/1246 (4.5) 1.9
(1.0-3.4)
0.04
HR, 95%CI estimated by Cox proportional model adjusted by sex, age, treatment arm, baseline LDL-C, baseline HDL-C, hypertension, chronic kidney disease
(estimated glomerular filtration rate <60), and smoking status.
Hazard ratio
0
3
2
1
Diet alone
ˎˎ
ˎ
Diet + pravastatin
<6.0
6.0–<6.5
≥6.5
HbA1c, %
Figure 1 Relation between HbA1c and CVD according to treatment arms. P-values were calculated against <6.0% in each group by Cox
proportional hazard model adjusted for sex, age, baseline LDL-C, baseline HDL-C, hypertension, chronic kidney disease (estimated glomerular
filtration rate <60), and smoking. *p <0.05; **p <0.01.
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ment of CVD in patients with type 2 diabetes and that
multidisciplinary interventions that includes weight,
lipid and blood pressure control are needed to minimize
the CVD risk, in addition to glucose lowering[28]. Sta-
tins offer an important therapeutic option for the man-
agement of lipids, particularly in type 2 diabetes.
However, the relation between HbA1c and CVD was
u n a l t e r e ds u g g e s t i n gt h a ta ppropriate HbA1c manage-
ment is required in addition to lipids reduction. There
are some hypotheses for the mechanisms by which
hydrophilic statins may attenuate the deterioration of
abnormal glucose metabolism in diabetic patients [29].
However, the HbA1c level was not significantly different
between the diet plus pravastatin group and the diet
alone group throughout the study period, as we have
previously reported [19]. It is possible that adherence to
diet therapy was somewhat worse in the diet plus pra-
vastatin group than in the diet alone group, which may
o rm a yn o ti n f l u e n c et h eH b A 1 cl e v e l .H o w e v e r ,w ed o
not think we should focus on the effects of pravastatin
on HbA1c levels in this analysis because there was no
difference in HbA1c levels between the two groups.
There are two important limitations to the present ana-
lysis. First, it was conducted in patients whose TC was
5.7-6.0 mmol/L, and extrapolating these results to
patients with higher TC concentrations should be done
with caution. On the other hand, our patients had a
broad range of LDL-C levels (1.4-4.6 mmol/L). Thus it
appears that our findings may be quite generalizable. Sec-
ond, the small number of events in the MEGA Study may
affect the accuracy of the spline method. Therefore the
tail analysis of data for sex, LDL-C level, and treatment
arm were exploratory, especially in sparse tail area. In
addition, an earlier study showed that all-cause mortality
was increased in people with low HbA1c levels (<4.0%)
[30]. Although we cannot assess the relationship between
low HbA1c and high mortality because few patients with
low HbA1c levels were included in this analysis, we
should take this into account in clinical practice.
In conclusion, our results suggest that the HbA1c
level should be included in prediction models for CVD
risk. Controlling HbA1c independently of lipid manage-
ment is necessary to reduce the risk of CVD in diabetic
patients with elevated HbA1c.
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